Last week, Cereno Scientific published its Q4 report and BioStock had the opportunity to talk with CEO Sten R. Sörensen to learn more about the most important points in the report as well as the company’s direction in 2021. Sörensen emphasised Cereno Scientific’s significant progress made towards reaching phase II with CS1 in pulmonary arterial hypertension (PAH) patients, the importance of the collaboration with CRO Worldwide Clinical Trials and outlined some milestones for 2021.
Watch the full interview (in Swedish) with Cereno Scientific’s CEO Sten R. Sörensen below:
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
The Nordic region’s leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto
